RxDoctor Payments Data

Mark Velarde, MD

Family Medicine · Wescosville, PANPI 1578513560

Payments from drug & device makers

$9,692in general payments, 2019–2025

Across 565 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$982
  • Boehringer Ingelheim$622
  • Johnson & Johnson$493
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$9,60199%
  • Education$911%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,692 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$89,712
Medicare patients
242
Services billed
1,325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban163$95,646
TrulicityDulaglutide42$53,123
RexultiBrexpiprazole38$41,423
JanuviaSitagliptin Phosphate31$36,497
XareltoRivaroxaban53$36,260
JanumetSitagliptin Phos/Metformin Hcl33$26,782
OzempicSemaglutide15$23,888
MounjaroTirzepatide16$23,660
TradjentaLinagliptin40$21,912
MyrbetriqMirabegron29$17,484
Breo ElliptaFluticasone/Vilanterol21$8,259
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,630
RocklatanNetarsudil Mesylat/Latanoprost19$7,436
LinzessLinaclotide11$6,625
Brimonidine Tartrate70$6,500

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$461$95,646163 claims
Lilly USA, LLCTrulicity, Mounjaro$1,283$76,78358 claims
MerckJanuvia, Janumet$349$63,27964 claims
Otsuka America Pharmaceutical, Inc.Rexulti$60$41,42338 claims
Johnson & JohnsonXarelto$493$36,26053 claims
Novo NordiskOzempic$982$23,88815 claims
Boehringer IngelheimTradjenta$622$21,91240 claims
Astellas Pharma US IncMyrbetriq$103$17,48429 claims
GSKBreo Ellipta, Arnuity Ellipta$151$10,87333 claims
AbbVieLinzess, Combigan$1,435$10,64028 claims
AstraZenecaBreztri Aerosphere$1,504$7,63011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Wescosville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →